|
| Status |
Public on Dec 01, 2017 |
| Title |
HAdMSC_d7_1 |
| Sample type |
RNA |
| |
|
| Source name |
TRA-1-60 (+) cells expressing OSKM on day 7 derived from Human adipose-derived mesenchymal stem cells, replicate1
|
| Organism |
Homo sapiens |
| Characteristics |
cell type: Reprogramming cells
|
| Treatment protocol |
The samples on day3 were EGFP (+) cells collected by flow cytometry. TRA-1-60 (+) cells on days 7-28 were collected by magnetic activated cell sorting.
|
| Growth protocol |
Somatic cell lines were maintained in appropriate conditions according to manufacturer's recommendation. TRA-1-60 (+) cells and iPSCs were maintained on SNL feeders in Primate ESC medium (ReproCELL) supplemented with 4 ng/ml basic fibroblast growth factor at 37 ºC in a humidified incubator with 5% CO2.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was prepared using the miReasy Purification kit (Qiagen) following the manufacturer's recommendations, and quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies).
|
| Label |
Cy3
|
| Label protocol |
Manufature's protocol
|
| |
|
| Hybridization protocol |
Manufature's protocol
|
| Scan protocol |
Slides were scanned on the G2565CA Microarray Scanner System (Agilent).
|
| Description |
TRA-1-60 (+) cells expressing OSKM on day 7 derived from Human adipose-derived mesenchymal stem cells, replicate1
|
| Data processing |
GeneSpring GX. Signals were normalized to percentile.
|
| |
|
| Submission date |
Nov 02, 2016 |
| Last update date |
Dec 01, 2017 |
| Contact name |
Kazutoshi Takahashi |
| E-mail(s) |
kazu@cira.kyoto-u.ac.jp
|
| Organization name |
Kyoto University
|
| Department |
Center for iPS Cell Research and Application
|
| Street address |
53 Kawahara-cho, Shogoin, Sakyo-ku
|
| City |
Kyoto |
| ZIP/Postal code |
606-8507 |
| Country |
Japan |
| |
|
| Platform ID |
GPL13607 |
| Series (1) |
| GSE89455 |
Proliferation pause as an early blockade of human cellular reprogramming toward pluripotency |
|
